UPDATE: Goldman Sachs Downgrades United Therapeutics to Neutral
Goldman Sachs is out with its report today on United Therapeutics (NASDAQ: UTHR), downgrading UTHR from Buy to Neutral.
In its report, Goldman Sachs writes, "We are downgrading UTHR to Neutral from Buy and upgrading ONXX to Buy from Neutral. Our downgrade of UTHR does not imply a change in our constructive view. But with less upside to our UTHR target (+17%), we see a more favorable combination of catalysts and upside potential in ONXX (NASDAQ: ONXX), which we upgrade to Buy with a 12-month $40 target (27% upside)."
Goldman Sachs maintains a $52 PT on UTHR.
Shares of UTHR closed Wednesday at $44.28, up 0.82% from Tuesday's close.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.